Latest News

{{header-clinical-trials-navigation}} Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04506567 Sponsor: Weill Medical College of Cornell University Phase: Phase 1/Phase 2 Eligibility: Age: minimum 18 Years maximum 99 Years Gender: Male Inclusion Criteria: 1. Histologically […]

{{header-clinical-trials-navigation}} Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors Condition: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma Study Type: Interventional Clinical Trials […]

{{header-clinical-trials-navigation}} ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901) Condition: Metastatic Castration-Resistant Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04419402 Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group Phase: Phase […]

{{header-clinical-trials-navigation}} A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies Condition: Clear-Cell Renal Cell Carcinoma Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04518046 Sponsor: Mirati Therapeutics Inc. Phase: Phase 1 Eligibility: Age: minimum 18 Years maximum N/A […]

To review the current literature on quality of care in the diagnosis and management of early-stage testicular cancer. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies on quality of care in testicular cancer diagnosis and management from January 1980 to August 2018.

Background Sorafenib (Sor) remains a first-line option for hepatocellular carcinoma (HCC) or refractory renal cell carcinomas (RCC). PLC/PRF/5 HCC model showed upregulation of hypoxia with enhanced efficacy when Sor is combined with hypoxia-activated prodrug evofosfamide (Evo).

The aim of the study was to assess the efficacy and safety of an enhanced recovery program (ERP) after robot-assisted partial nephrectomy (RAPN) for cancer. It was a monocentric, retrospective, comparative study.

The data regarding oncological outcome in advanced renal cell carcinoma (RCC) arising in end-stage renal disease (ESRD) are limited. Patients diagnosed with advanced RCC on maintenance dialysis therapy (ESRD-RCC) and treated with tyrosine kinase inhibitors (TKIs) were retrospectively evaluated.

We assessed sociodemographic factors associated with and survival implications of refusal of potentially survival-prolonging locoregional treatment (LT, including radiotherapy and surgery) despite provider recommendation among men with localized prostate adenocarcinoma.

Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration-resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with […]